Comparative Pharmacology
Head-to-head clinical analysis: CONEXXENCE versus GENCEPT 10 11 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONEXXENCE versus GENCEPT 10 11 28.
CONEXXENCE vs GENCEPT 10/11-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CONEXXENCE is a combination hormonal contraceptive that suppresses gonadotropin (FSH and LH) release via inhibition of hypothalamic GnRH, thereby preventing ovulation. The progestin component (desogestrel) also increases cervical mucus viscosity and alters endometrial receptivity.
Combination of ethinyl estradiol (estrogen) and levonorgestrel (progestin) inhibits ovulation by suppressing gonadotropin release, increases cervical mucus viscosity to impede sperm penetration, and alters endometrial receptivity.
CONEXXENCE is not a recognized pharmaceutical agent. No standard dosing information available.
One tablet (ethinyl estradiol 0.01 mg/levonorgestrel 0.1 mg) orally once daily for 28 days. For the first 21 days, active tablets are taken; the next 7 days are placebo tablets.
None Documented
None Documented
Terminal elimination half-life: 12–18 hours; allows twice-daily dosing; prolonged in severe renal impairment (up to 40 hours).
Terminal elimination half-life is approximately 8-12 hours. Steady state is achieved within 2-3 days.
Renal: 70% unchanged; fecal: 30% (including metabolites).
Renal excretion accounts for approximately 70% of elimination (as unchanged drug and metabolites), with about 10% biliary/fecal. The remaining is metabolized.
Category C
Category C
Oral Contraceptive
Oral Contraceptive